SHERIDAN, WYOMING – May 8, 2025 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, today revealed the successful outcome of all proposed resolutions at its 2025 Annual General Meeting (AGM). Among the significant decisions, shareholders approved key appointments to the Board, including the election of Deborah Di Sanzo, and granted approval for the 2024 Compensation Report and the Report on Non-Financial Matters.
SHERIDAN, WYOMING – May 8, 2025 – Alcon, the global leader in eye care, has announced its continued partnership with the Association for Research in Vision and Ophthalmology (ARVO) for the Eye Pitch live event, set to take place at the ARVO 2025 annual meeting in Salt Lake City, Utah, on May 3, 2025. This event will serve as a platform for entrepreneurs and researchers within the ophthalmic community to present groundbreaking ideas aimed at transforming eye care.
SHERIDAN, WYOMING – May 8, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today introduced the Elecsys® PRO-C3 test, a groundbreaking diagnostic solution designed to assess liver fibrosis severity in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). This innovative test, developed in partnership with Nordic Bioscience, provides healthcare providers with a fast and efficient way to evaluate liver fibrosis, a disease that contributes to one in every 25 deaths globally.
SHERIDAN, WYOMING – May 8, 2025 – Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), used for treating HER2-positive breast cancer. The label update will allow for Phesgo to be administered outside of clinical settings, such as at patients’ homes, under the supervision of a healthcare professional.
SHERIDAN, WYOMING – May 8, 2025 – Roche has achieved a significant milestone in oncology diagnostics with the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This marks the first FDA recognition for a computational pathology companion diagnostic (CDx) device using artificial intelligence, highlighting Roche's continued leadership in cancer diagnostics and precision medicine.
SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced that Marc N. Casper, the company’s chairman, president, and chief executive officer, will be presenting at the highly anticipated BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 11:40 a.m. (ET). The presentation will be available via a live webcast, accessible through the Investors section of Thermo Fisher’s official website.
SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced a significant $2 billion investment over the next four years, aimed at enhancing U.S. innovation and manufacturing across the life sciences sector. This strategic investment underscores Thermo Fisher's continued confidence in America's ability to lead global scientific advancement while further supporting biopharma companies in the development and production of life-saving medicines.
SHERIDAN, WYOMING – May 08, 2025 – Agilent Technologies Inc. (NYSE: A) has introduced its highly anticipated Seahorse XF Flex Analyzer, an advanced, high-performance 24-well system designed to propel metabolic analysis in complex 3D tissue and organoid models. This groundbreaking tool, accompanied by dedicated consumables and kits, promises to transform the way researchers study cellular metabolism, providing critical insights into disease mechanisms and therapeutic development.
SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) is set to highlight its groundbreaking solutions and strategic collaborations at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25-30, 2025. Agilent’s innovative products, including advanced DNA cancer panels, multiomic profiling assays, and cutting-edge companion diagnostics, will take center stage, reflecting the company’s commitment to advancing cancer research and therapeutic development.
SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) has announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has achieved European IVDR certification. This certification positions the assay as a Companion Diagnostic (CDx) to identify gastric or gastroesophageal junction (GEJ) adenocarcinoma patients eligible for treatment with KEYTRUDA® (pembrolizumab), a leading anti-PD-1 therapy developed by Merck.